Frazier Healthcare Partners has closed the Frazier Life Sciences Public Fund, exceeding its target and closing on nearly USD830 million in capital commitments in an oversubscribed fundraise.
Led by Managing Partner Albert Cha, General Partner and Portfolio Manager Jamie Brush, and Managing Partners Patrick Heron and James Topper, Frazier Life Sciences Public Fund is a long-only fund investing in small- and mid-cap public biotech companies. Frazier Life Sciences Public Fund marks Frazier’s first dedicated public life sciences fund, bringing the firm’s total committed capital raised since inception to over USD7.1 billion.
“We are thrilled to announce the launch of our public life sciences fund,” says Albert Cha, managing partner on the Frazier Life Sciences team. “We are extremely grateful to our limited partners for their support.”
Recent exits of Frazier Life Sciences public investments include ARMO BioSciences (acquired by Eli Lilly), Ignyta (acquired by Roche), Rocket Pharmaceuticals (NASDAQ: RCKT), Translate Bio (NASDAQ: TBIO, acquired by Sanofi), and Trillium Therapeutics (NASDAQ: TRIL, pending acquisition by Pfizer).
